These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
824 related articles for article (PubMed ID: 28069043)
1. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
2. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Gao L; Shay C; Lv F; Wang X; Teng Y Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785 [TBL] [Abstract][Full Text] [Related]
3. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation. Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355 [TBL] [Abstract][Full Text] [Related]
4. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling. Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455 [TBL] [Abstract][Full Text] [Related]
5. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622 [TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503 [TBL] [Abstract][Full Text] [Related]
7. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573 [TBL] [Abstract][Full Text] [Related]
8. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595 [TBL] [Abstract][Full Text] [Related]
10. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398 [TBL] [Abstract][Full Text] [Related]
11. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785 [TBL] [Abstract][Full Text] [Related]
12. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735 [TBL] [Abstract][Full Text] [Related]
13. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560 [TBL] [Abstract][Full Text] [Related]
14. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Kaibori M; Sakai K; Ishizaki M; Matsushima H; De Velasco MA; Matsui K; Iida H; Kitade H; Kwon AH; Nagano H; Wada H; Haji S; Tsukamoto T; Kanazawa A; Takeda Y; Takemura S; Kubo S; Nishio K Oncotarget; 2016 Aug; 7(31):49091-49098. PubMed ID: 27384874 [TBL] [Abstract][Full Text] [Related]
15. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. Tao Z; Cui Y; Xu X; Han T Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047 [TBL] [Abstract][Full Text] [Related]
16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356 [TBL] [Abstract][Full Text] [Related]
18. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Azumi J; Tsubota T; Sakabe T; Shiota G Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977 [TBL] [Abstract][Full Text] [Related]
19. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237 [TBL] [Abstract][Full Text] [Related]
20. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma. Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]